Daphne Karydas Acquires Shares in Mineralys Therapeutics

On June 17, 2026, Daphne Karydas made a notable purchase of 3,000 shares of Mineralys Therapeutics, Inc. (NasdaqGS: MLYS). The shares were acquired at an average price of $12.02 each, amounting to a total investment of $36,060. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Mineralys Therapeutics, Inc.

On the same day, David Malcom Rodman, the Chief Medical Officer, also engaged in transactions involving 4,584 shares. Both insiders executed these trades outside of any pre-planned trading arrangements.

Other Institutional Activity in Mineralys Therapeutics

Several institutional investors have been active in Mineralys recently. RA Capital Management, L.P. increased its holdings by 369,000 shares, bringing its total to 7,692,750 shares valued at approximately $208.4 million. BlackRock, Inc. added 153,904 shares, reaching 4,481,582 shares worth about $121.4 million. Meanwhile, Wellington Management Group LLP made a significant addition of 2,574,801 shares, resulting in a total of 3,359,068 shares valued at roughly $90.0 million. In contrast, FMR LLC reduced its stake by 196,405 shares, leaving it with 4,861,104 shares valued at about $131.7 million.

Mineralys Therapeutics Stock Snapshot

Mineralys Therapeutics shares are currently trading near $23.99. The company has a market capitalization of approximately $2.11 billion. It is not yet profitable, as indicated by its negative forward P/E ratio of -11.44. The stock's beta is 0.565, reflecting lower volatility compared to the broader market. Over the past year, the stock has traded between $12.59 and $47.65. The 50-day moving average stands at $27.72, while the 200-day moving average is $33.07. The company boasts strong liquidity with a current ratio of 44.33 and a quick ratio of 43.90.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on Mineralys Therapeutics. On March 13, 2026, B of A Securities reiterated its buy rating with a price target of $51.00. The consensus among eight analysts is a strong buy, with a mean target price of $49.00.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc., headquartered in Radnor, Pennsylvania, is a biopharmaceutical company focusing on developing treatments for diseases caused by dysregulated aldosterone. The company is working on lorundrostat, a selective aldosterone synthase inhibitor, targeting conditions like hypertension and chronic kidney disease. Led by CEO Dr. Jon Congleton, Mineralys is part of the healthcare sector, specifically within the biotechnology industry.

Bottom Line

Daphne Karydas' recent purchase of Mineralys Therapeutics shares highlights continued insider interest in the company's growth prospects. Mineralys, with its focus on innovative treatments, remains a significant player in the biotech sector. Investors often track such insider transactions as potential indicators of confidence in the company's future. However, it's important to remember that these insights are based on past filings and may not reflect current positions.